Navigation Links
Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
Date:10/23/2011

iRNAs, as Silence has clearly been shown to be at the forefront of efficient and safe delivery of siRNAs and miRNAs, a process critical to the ultimate success of what promises to be a new and exciting class of targeted cancer therapeutics. Mirna has developed a strong intellectual property position in the therapeutic use of miRNAs in cancer, and has established a broad pipeline of key tumor suppressor miRNAs as potential new targeted therapeutic candidates against both solid and haematological cancers. An efficient delivery technology that provides for systemic delivery of therapeutically effective dose-levels of these miRNAs to their intended targets is a key element in their potential success in the clinic."

Silence's proprietary lipid delivery technology AtuPLEX™ has demonstrated the broad systemic delivery to the vascular endothelium. Formulations generated with the AtuPLEX™ technology can be lyophilized (freeze dried) significantly improving stability, shipping and handling.

Silence is currently conducting a Phase I trial with Atu027 which is based on AtuPLEX™ in patients with advanced solid cancer. Interim data analysis from this trial were presented at the 2011 American Society of Clinical Oncology conference and showed that Atu027 is safe and well tolerated and provided broad support for AtuPLEX™ as an effective siRNA delivery technology with the potential to overcome the recognized delivery challenges currently associated with RNAi therapeutics.

DBTC is the latest delivery system developed by scientists at Silence and allows functional targeted delivery to the liver. Unlike Silence's established delivery technologies, DBTC is a novel lipid-based formulation that functionally delivers to liver endothelial cells, hepatocytes and to other cell types of the liver. As with AtuPLEX™, DBTC can be lyophilized.

Notes for editors                 <
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
2. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
3. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Silence Therapeutics Appoints New Vice President of Research
8. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
11. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... are being held to solicit public sentiment on Assembly ... 45 . The bills were introduced to the state legislature ... and parthenogenesis (the process of manipulating the genetic material of ... material from any other cell, in a way that causes ...
... just go bad. Not so often, components that supply power ... case beginning at 11:57 p.m. Monday night with TDS Internet ... and downed dial-up and DSL users en masse, TDS Telecom ... restored at 2:40 a.m. to all users. , ,TDS Internet ...
... determined to give heavy email users something they lack: time and ... a heavy email user, talks about the inspiration for his company, ... world. , , WTN: How much email do you get everyday? ... messages a day from various email accounts with about 70% of ...
Cached Biology Technology:Public Hearing Held for controversial anti-cloning bills 2Public Hearing Held for controversial anti-cloning bills 3Public Hearing Held for controversial anti-cloning bills 4TDS Suffers 29-State System Outage 2TDS Suffers 29-State System Outage 3WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 2WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 3
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... BOULDER, Colo., September 11, 2012 BiOptix announced continued support ... in BioWest 2012, a leading life sciences showcase ... City Center. "BiOptix continues to believe in the ... Association, noted Rick Whitcomb, President and CEO of ...
... screening technique developed by researchers at the RIKEN Plant ... novel immune-priming compounds in Arabidopsis plants. Discovery ... plant growth or crop yield, establishes the new technique ... crops from damaging pathogens. Plant activators, compounds that ...
... Mich.A strip of glass covered in hairy nanoparticles can ... system, and other toxic metals in fluids. ... Northwestern University and the University of Michigan found that ... common form of mercury pollution, at unprecedentedly small concentrations. ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Screening technique uncovers 5 new plant activator compounds 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 3
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
PFM8 Antibody...
Biology Products: